Cell cycle checkpoints, e.g., ATR and CHK1 are active therapeutic targets in numerous cancers including HGSOC either as a monotherapy or as a sensitizer of DNA damaging drugs and radiation therapy [25–27]. Here, CHEK1 is linked to cancer.